Skip to content

Baxter International BAX Net Revenue Royalties — Maximum contingent future payments

Discontinued — last reported Q1 '18

Similar metrics at other companies

Neurocrine Biosciences logo
NBIXRoyalty — Potential milestone payment receipts
$366M
Natera, Inc. logo
NTRARoyalty — Deferred Revenue
$500K-64.3%
Cytokinetics logo
CYTKRights Granted — Nonrefundable Payment Obligation
$40M
Axsome Therapeutics logo
AXSMRoyalty And Milestone Revenue — Revenue
$1.8M+63.2%
Neurocrine Biosciences logo
NBIXLicense — Potential milestone payment receipts
$55M
Natera, Inc. logo
NTRARoyalty — Revenue Remaining Performance Obligation
$20M

Other financials

Income statement

See full
Revenue$2.7B+2.9%
Gross profit$891.0M+3.5%
Operating income$66.0M+13.8%
Net income-$15.0M-112%
EPS (diluted)-$0.03-112%

Balance sheet

See full
Cash & equivalents$2.0B-12.1%
Total debt$224.0M-8.9%
Total equity$6.0B-14.7%
Total assets$19.8B-6.8%

Cash flow

See full
Operating cash flow$213.0M+210%
CapEx$128.3M+15.0%
Free cash flow$83.0M-42.1%

Valuation

See full
Market cap$10.27B-50.6%
Enterprise value$8.48B-55.6%
P/S0.9×-1.0×

Profitability

See full
Gross margin30.1%-5.9pp
Operating margin-2.7%
Net margin-9.7%+62.5pp
FCF margin3%-2.4pp

Returns & leverage

See full
Return on equity-16.7%-76.7pp
Debt / equity0.0×
Current ratio1.9×-0.2×

Where this comes from

Reported directly by Baxter International in its filing.

Tagged under the XBRL concept us-gaap:BusinessCombinationContingentConsiderationArrangementsRangeOfOutcomesValueHigh.

The official record: Baxter International’s 10-K, filed February 11, 2021, on SEC EDGAR. View the filing →

Questions, answered.

What does net revenue royalties — maximum contingent future payments mean?
The maximum amount of money the company might have to pay to partners based on future sales milestones.
How do you interpret net revenue royalties — maximum contingent future payments?
An increase suggests higher potential future obligations tied to successful product performance, while a decrease indicates a reduction in contingent liabilities or the expiration of milestone periods.
How does net revenue royalties — maximum contingent future payments compare across companies?
Comparable to contingent consideration or milestone payment obligations reported by other medical device and pharmaceutical companies that rely on in-licensed technology.